CHICO, Calif.--(BUSINESS WIRE)--NuvoLase, Inc., the first company to receive FDA clearance to market the PinPointe FootLaser for nail disorders (OR DISEASED NAILS) caused by onychomycosis (nail fungus), announced today they have received marketing clearance for the PinPointe FootLaser from the Australian Therapeutic Goods Administration (TGA). Before any medical device can be supplied in Australia, it must be included in the Australian Register of Therapeutic Goods (ARTG) that is governed by the TGA.
Help employers find you! Check out all the jobs and post your resume.
